Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2015; 21(35): 10251-10252
Published online Sep 21, 2015. doi: 10.3748/wjg.v21.i35.10251
Published online Sep 21, 2015. doi: 10.3748/wjg.v21.i35.10251
Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin’s lymphoma
Hasan Tahsin Gozdas, Department of Infectious Diseases and Clinical Microbiology, Dr. Münif İslamoğlu Kastamonu State Hospital, 37100 Kastamonu, Turkey
Erkan Arpaci, Department of Medical Oncology, Bülent Ecevit University Faculty of Medicine, 67980 Zonguldak, Turkey
Author contributions: Both authors contributed to this work.
Conflict-of-interest statement: The authors declare no conflict of interest related to this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Hasan Tahsin Gozdas, Department of Infectious Diseases and Clinical Microbiology, Dr. Münif İslamoğlu Kastamonu State Hospital, 37100 Kastamonu, Turkey. dr.htgozdas@yahoo.com.tr
Telephone: +90-3662141053 Fax: +90-3662142427
Received: March 2, 2015
Peer-review started: March 4, 2015
First decision: April 13, 2015
Revised: April 21, 2015
Accepted: June 9, 2015
Article in press: June 9, 2015
Published online: September 21, 2015
Peer-review started: March 4, 2015
First decision: April 13, 2015
Revised: April 21, 2015
Accepted: June 9, 2015
Article in press: June 9, 2015
Published online: September 21, 2015
Core Tip
Core tip: Lamivudine is used for the prevention of hepatitis B virus (HBV) reactivation in patients receiving immunochemotherapy. Following cessation of lamivudine prophylaxis, HBV reactivation can be observed because of insufficient duration of prophylaxis. If HBV DNA is moderately elevated at that moment, prophylaxis may be continued with lamivudine instead of entecavir.